EMAs Response to my Mail i sent them explaining the importance of Finasteride for hairloss in EU 2/5/2025
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Possible Finasteride ban happening soon
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.
community Brotzu lotion update
A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.
community European Medecine Agency (EMA) review of Finasteride and Dutasteride
Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
community Heads up for EU Fin users: Finasteride prescription has been toughened up in France
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
community Why is there no 10mg (or atleast higher than 0.5mg) dutasteride capsules
Higher doses of dutasteride for hair loss are debated, with some users suggesting they are unnecessary and potentially unsafe. The original poster uses a combination of dutasteride, minoxidil, and RU58841 for hair regrowth, despite concerns about high dosages.
community Real world data from Europe shows that DUT is significantly safer than FIN in long term use
Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.
Related Research
6 / 6 results
research Finasteride-Induced Neuropsychiatric Reactions
This review suggests a causal relationship between finasteride, used for hair loss, and persistent neuropsychiatric side effects like depression, citing evidence that fulfills key causality criteria and calls for cautious use along with strengthened regulatory oversight.
research 5α-reductase Inhibitors: Finasteride and Dutasteride in Feminising Therapy
This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.
research Medicalisation, pharmaceutical promotion and the Internet: a critical multimodal discourse analysis of hair loss websites
This study analyzes how commercial websites for Propecia depict male hair loss and promote medical treatment, suggesting they contribute to medicalizing a natural condition for profit.
research Interventions for female pattern hair loss
This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.
research Farmácia dos Clérigos - Porto e nos Serviços Farmacêuticos da University College Hospital - Londres, Reino Unido, ao abrigo do programa Erasmus+
Pharmacists play a crucial role in improving patient outcomes through personalized care and staying updated with scientific advancements.
research Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study
This study found that using electronic healthcare record data can provide valuable early insights into the clinical context of about half of the new safety signals evaluated within a regulatory environment.